The aims of this study were designed to determine whether liraglutide, a long-acting
glucagon-like peptide, could reverse the adverse effects of a diet high in fat that also …

OBJECTIVE The efficacy of liraglutide, a human glucagon-like peptide-1 (GLP-1) analog, to
prevent or delay diabetes in UCD-T2DM rats, a model of polygenic obese type 2 diabetes …

Liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, has been demonstrated to reduce
hepatic steatosis. However, the mechanism of the lipid-lowering effect of liraglutide in the …

Abstract Glucagon like peptide-1 (GLP-1) promotes postprandial insulin secretion.
Liraglutide, a full agonist of the GLP-1 receptor, reduces body weight, improve insulin …

Background—Cardiac consequences of obesity include inflammation, hypertrophy, and
compromised energy metabolism. Glucagon-like peptide-1 is an incretin hormone capable …

We investigated the effects of liraglutide on insulin sensitivity and glucose metabolism in
male Wistar rats. The rats were fed a normal chow diet (NCD) or a 60% high-fat diet (HFD) …

Aim: Liraglutide is a long‐acting glucagon‐like peptide‐1 (GLP‐1) mimetic which is a
treatment option for type 2 diabetes. GLP‐1 peptides, including Liraglutide, cross the blood …

Background Many chronic metabolic diseases, such as obesity and type 2 diabetes (T2DM),
are closely related to a chronic low-grade inflammatory state in tissues. The high prevalence …

Objectives: To evaluate the efficacy of liraglutide, a new, stable, once‐daily human analog of
glucagon‐like peptide‐1, in a new animal model of obesity. Research Methods and …

Metabolic effects of the glucagon-like peptide-1 analog liraglutide and the dipeptidyl
peptidase-IV inhibitor vildagliptin were compared in rats made obese by supplementary …